Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

BACKGROUND: Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to anticancer drug resistance, but such correlation is unclear in sorafenib resistance of HCC. METHODS: Six sorafenib-naive HCC cell li...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shen, Y-C, Ou, D-L, Hsu, C, Lin, K-L, Chang, C-Y, Lin, C-Y, Liu, S-H, Cheng, A-L
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553537/
https://ncbi.nlm.nih.gov/pubmed/23257894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.559
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars